EAF2 and prostate carcinoma: Ai et al. observed that EAF2 and Pten double-deficient (EAF2−/−Pten+/−) mice exhibited a higher rate of prostate cancer compared with animals with EAF2 or PTEN deletion alone, and concurrent EAF2 and PTEN deficiency activates Akt and p44/42 signaling pathways (Ai et al., 2014).